Results 241 to 250 of about 660,646 (336)

Similar long-term outcome for arterial myocardial revascularization performed after or within the first seven day of acute myocardial infarction

open access: diamond, 2013
Nachum Nesher   +8 more
openalex   +2 more sources

The difficult discussion on the deactivation of implantable cardioverter devices at the end of life: a systematic review

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 733-760, April 2025.
Abstract Implantable cardioverter defibrillators (ICDs) reliably prevent death due to life‐threatening arrhythmias; this may become less relevant in people with more severe heart failure who are reaching the end of life (EOL). This review aimed to explore the ICD deactivation process and identify ethical issues, especially around the initiation of ...
Siobhan C. Murray   +2 more
wiley   +1 more source

Daylight Savings Time and Acute Myocardial Infarction.

open access: yesJAMA Netw Open
Rymer JA   +8 more
europepmc   +1 more source

Dream Patterns in Patients with Acute Myocardial Infarction: Data from the STEP-IN-AMI Trial. [PDF]

open access: yesJ Clin Med
Roncella A   +7 more
europepmc   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang   +7 more
wiley   +1 more source

Transfer learning for predicting acute myocardial infarction using electrocardiograms. [PDF]

open access: yesPLOS Digit Health
Nyström A   +5 more
europepmc   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler   +4 more
wiley   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy